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Abstract
Drug resistance has always been one of the most important impediments to global malaria control. Artemisinin resistance
has recently been confirmed in the Greater Mekong Subregion (GMS) and efforts for surveillance and containment are
intensified. To determine potential mechanisms of artemisinin resistance and monitor the emergence and spread of
resistance in other regions of the GMS, we investigated the in vitro sensitivity of 51 culture-adapted parasite isolates from
the China-Myanmar border area to four drugs. The 50% inhibitory concentrations (IC50s) of dihydroartemisinin, mefloquine
and lumefantrine were clustered in a relatively narrow, 3- to 6-fold range, whereas the IC50 range of artesunate was 12-fold.
We assessed the polymorphisms of candidate resistance genes pfcrt, pfmdr1, pfATP6, pfmdr6 and pfMT (a putative
metabolite/drug transporter). The K76T mutation in pfcrt reached fixation in the study parasite population, whereas point
mutations in pfmdr1 and pfATP6 had low levels of prevalence. In addition, pfmdr1 gene amplification was not detected.
None of the mutations in pfmdr1 and pfATP6 was associated significantly with in vitro sensitivity to artemisinin derivatives.
The ABC transporter gene pfmdr6 harbored two point mutations, two indels, and number variations in three simple repeats.
Only the length variation in a microsatellite repeat appeared associated with altered sensitivity to dihydroartemisinin. The
PfMT gene had two point mutations and one codon deletion; the I30N and N496– both reached high levels of prevalence.
However, none of the SNPs or haplotypes in PfMT were correlated significantly with resistance to the four tested drugs.
Compared with other parasite populations from the GMS, our studies revealed drastically different genotype and drug
sensitivity profiles in parasites from the China-Myanmar border area, where artemisinins have been deployed extensively for
over 30 years.
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Introduction
The development and spread of multidrug resistant (MDR)
Plasmodium falciparum has led to the adoption of artemisinin-based
combination therapies (ACTs) as the first-line treatment for
falciparum malaria in most malaria-endemic countries of the
world [1]. Artemisinin and its derivatives are by far the most
potent antimalarial drugs [2], and at present, our last line of
defense against multidrug resistant parasites. Therefore, the
recently confirmed emergence of artemisinin resistance in western
Cambodia is a major threat for current initiatives to control and
eliminate malaria [3–5]. Because this exact same area has been the
origin of both chloroquine (CQ) and sulfadoxine-pyrimethamine
resistance, both of which have subsequently spread to Africa [6,7],
the consequence of a similar spread of artemisinin resistance will
be catastrophic. While limited evidence suggests that artemisinin
resistance has not yet spread to other areas [8], the World Health
Organization (WHO) is coordinating a large-scale elimination
campaign in this region aiming to contain artemisinin resistance
[9,10]. Apparently, containment efforts require better resistance
surveillance [11], but this is hampered due to the lack of
convenient molecular surveillance tools for detecting artemisinin
resistance. At this moment, the most reliable way of detecting
artemisinin resistance is through rigorous clinical efficacy studies,
which are expensive and time-consuming.
The mode of action of artemisinins in malaria parasites is still
a debated topic and the molecular basis of reduced artemisinin
susceptibility is unclear [12–14]. To date, a few genes have been
postulated to be associated with artemisinin resistance. The P.
falciparum multiple drug resistance 1 (pfmdr1) gene has received the most
attention, beacuse several mutations (N86Y, Y184F, S1034C,
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N1042D, and D1246Y) occurring in PfMDR1 from field isolates
are associated with altered sensitivity to multiple structurally
unrelated antimalarials such as CQ, mefloquine (MQ), quinine
(QN), halofantrine (HF), and artemisinins [15–19]. In addition,
pfmdr1 amplification is a key determinant for both in vivo and in vitro
resistance to MQ and HF [19–23]. Increased pfmdr1 copy number,
which is more prevalent in west Cambodia, is associated with
increased risk of therapy failures of artesunate (AS)-MQ, the major
ACT deployed in Thailand and Cambodia [24–28]. The sarco/
endoplasmic reticulum calcium-dependent ATPase (SERCA)
homologue PfATP6 has been considered as a specific target of
artemisinins, since artemisinin derivatives inhibit this enzyme
expressed in Xenopus oocytes [29] and this inhibition was abolished
by the introduction of the L263E mutation in the predicted
transmembrane domain 3 of PfATP6 [30]. Another mutation
(S769N) has been linked to artemether resistance in P. falciparum
field isolates from French Guiana [31]. However, the L263E
mutation has not been found in field isolates from most malaria
endemic areas, and S769N is very rare [32–40]. Though multiple
new single nucleotide polymorphisms (SNPs) have been detected
in pfatp6, their associations with artemisinin resistance have not
been established. Mutations in several other genes also have been
suggested to be responsible for artemisinin resistance. Mutations in
the UBP1 gene encoding a deubiquitination enzyme have been
identified to confer artemisinin resistance in the rodent malaria
parasite P. chabaudi [41]. However, the equivalent mutations have
not been found in P. falciparum field isolates from Cambodia and
Thailand [42]. Recently, using a genome-wide association
approach, Mu et al. detected signs of positive selection at several
putative transporter genes in parasite populations including one
coding the ABC transporter pfmdr6 and another gene coding the
metabolite/drug transporter pfMT [43,44]. So far, none of the
candidate genes have been conclusively shown to be responsible
for artemisinin resistance. Therefore, further research is needed to
identify the causal mutations for artemisinin resistance.
Malaria is still a serious public health problem in the Greater
Mekong Subregion (GMS), which includes Cambodia, Laos,
Thailand, Vietnam, Myanmar and China [45]. Within this region,
malaria transmission is particularly intense along international
border areas. The GMS is historically a hotspot of antimalarial
drug resistance, and resistance management remains a high
priority for malaria control. The China-Myanmar border area has
the longest history of artemisinin monotherapy; it has been used
for over three decades and in vitro studies have detected reduced
susceptibility to artemisinins [46]. Therefore, close surveillance of
artemisinin resistance in this area is necessary to detect and deter
resistance development. Here we report an assessment of in vitro
sensitivity of clinical P. falciparum isolates from the China-
Myanmar border area to four antimalarial drugs, AS, dihydroar-
temisinin (DHA), lumefantrine (LMF) and MQ. Using a candidate
gene approach, we want to determine whether polymorphisms in
these genes are associated with decreased drug sensitivity.
Materials and Methods
Parasite Samples and in vitro Culture
P. falciparum clinical isolates were collected in 2007–2009 from
symptomatic patients presenting with uncomplicated P. falciparum
infections attending a malaria clinic in Laiza township near the
China-Myanmar border. Malaria infections were diagnosed by
microscopic examination of Giemsa-stained thick and thin blood
films. To confirm monoclonal infections, parasites were genotyped
at three polymorphic genes, merozoite surface protein 1 (msp1), msp2
and glutamate-rich protein (glurp), using previously described methods
[47–49]. A total of 21, 9, and 21 parasite isolates were adapted to
continuous in vitro culture for the year 2007, 2008, and 2009,
respectively [50]. The human subject protocol for this study was
approved by the Institutional Review Board of Kunming Medical
University. Parasite routine culture was maintained in type O+
human red blood cells (RBCs) in complete medium supplemented
with 6% AB human serum under an atmosphere of 90% N2/5%
O2/5% CO2 [51].
In vitro Drug Sensitivity Assay
A SYBR Green I-based fluorescence assay was used to measure
parasite sensitivity to four antimalarial drugs: AS, DHA, MQ, and
LMF [52]. MQ was purchased from Sigma (St Louis, MO, USA),
while the other three drugs were obtained from Kunming
Pharmaceutical Co. (Kunming, Yunnan, China). The stock
solution of AS (0.260 mM), DHA (0.352 mM), MQ (2.56 mM),
and LMF (7.56 mM) were prepared in ethanol and 2-fold dilutions
were made in complete medium. Cultures were synchronized by
two rounds of sorbitol treatment, and late ring or early trophozoite
stage parasites were assayed for drug sensitivity in 96-well
microtiter plates at 5% hematocrit and 0.3% parasitemia. For
drug assays, 90 ml of parasite culture were seeded into each culture
well, and 10 ml of diluted drugs in complete medium solutions
were dispensed into each well to obtain a desired final
concentration. The plates were incubated at 37uC in a CO2
incubator for 72 h. The plates were then frozen at 280uC,
thawed, and mixed with 100 ml of lysis buffer. The plates were
incubated in the dark for about 1 h and fluorescence data were
acquired using the Fluoroskan Ascent FL microplate fluorometer
(Thermo Scientific, Waltham, MA). For each parasite isolate and
drug concentration, the assay was performed in three biological
replicates and each with three technical replicates. To reduce the
variations between plates, the standard laboratory clone 3D7 was
included as a reference. The in vitro drug response data were
entered into the SPSS data editor, and the geometric mean of the
half-maximal inhibitory concentration (IC50) was calculated for all
isolates using a regression-probit analysis. Standard deviation was
calculated using the mean values of the three biological replicates
of each parasite isolate.
Molecular Analysis of Candidate Genes
Parasite genomic DNA was isolated from cultured parasites
using a proteinase K digestion and phenol/chloroform extraction
procedure [53]. By using a PCR and sequencing approach, we
assessed SNPs in pfcrt, pfmdr1, pfatp6, a putative ABC transporter
PF13_0271 (pfmdr6), and a putative metabolite/drug transporter
PF14_0260 (pfMT). Two pfcrt fragments covering codons 76 and
220 and two pfmdr1 fragments including codons 86, 184, 1034,
1042 and 1246 were amplified as described previously [54]. Two
regions of pfatp6 gene (28–3065 and 3207–3952 bp) were
amplified using primers and conditions from previously published
work [36,55] (see Table S1). The coding sequences of pfmdr6 and
pfMT genes, shown to be under strong positive selection [43], were
amplified using primers shown in Table S1. To minimize errors
introduced in the sequences during PCR amplification, we used
Advantage HD DNA Polymerase Mix (Clontech, Mountain View,
CA), which has efficient 39 R 59 exonuclease activity for high
fidelity. PCR products were purified using a PCR Purification kit
(Qiagen, Valencia, CA) and used for direct sequencing. Over-
lapping sequences were obtained by using sequencing primers. For
singletons, the sequence was confirmed from two independent
PCR reactions from the same DNA templates. For a highly AT-
rich region in the pfMT gene, the primers MT_873 and mt_1433R
were used to amplify this fragment and the PCR products were
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cloned into the pGEM-T Easy Vectors system (Promega,
Madison, WI). Plasmid DNA was extracted by Zyppy Plasmid
Miniprep Kit (Zymo research, Orange, CA). For accuracy, at least
two clones were sequenced for each sample. Alignment of DNA
sequences were performed using the BioEdit program with the
3D7 sequence as the reference. All new sequences were deposited
in GenBank under the accession numbers (JN983240–JN983290
for pfatp6, JN983291–JN983341for pfmdr6, and JN983342–
JN983392 for pfMT).
Pfmdr1 copy number in field parasite isolates was determined by
real-time PCR using FastStart Universal SYBR Green Master Mix
on an ABI 7300 real-time PCR system (Applied Biosystems). DNA
from the reference strain 3D7, which has a single copy pfmdr1
gene, was included for calibration. The single copy b-tubulin gene
served as an internal control for estimating the copy number of
pfmdr1. Each reaction was performed in a final reaction volume of
20 ml. Copy number of pfmdr1 gene was calculated using the
22DDCt method as described earlier [56]. The efficiency of each
PCR (pfmdr1 and b-tubulin) was determined using a scale dilution of
DNAs from the laboratory lines 3D7 (containing 1 copy of pfmdr1)
and Dd2 (containing 3–4 copies of pfmdr1). Determination of the
copy number was done by comparison of the ratio of pfmdr1/b-
tubulin taking into account the efficiency of each PCR. Each
sample was analyzed in triplicate. Assays were repeated if one of
the following two results was obtained: Ct value .35, or copy
number as 1.3–1.6 or ,0.7.
Statistical Analysis
Spearman’s correlation coefficients were used to investigate the
degree and significance of the relation between the IC50 values of
the four drugs. It was chosen instead of Pearson’s in order to
provide robust correlation estimates despite potential outliers in
the data. We then used t-tests to look for significant differences in
mean IC50 values between these field isolates and 3D7, and
between the years. Finally, we used multiple t-tests and a gener-
alized linear model to investigate potential, significant differences
in mean IC50 values between haplotypes and point mutations for
each gene and for each drug. The Bonferroni correction was used
to control for the increased probability of false positives in multiple
comparisons. All statistical analyses were done using SAS version
9.2 (http://www.sas.com/) and R version 2.14.2 (http://cran.r-
project.org/).
Results
In vitro Drug Assays
To determine whether artemisinin resistance has emerged at the
China-Myanmar border area, we assessed in vitro sensitivity of 51
culture-adapted P. falciparum strains originating from this region to
two artemisinin derivatives AS and DHA and two aminoalcoholic
drugs MQ and LMF. These parasites were collected in 2007–2009
and genotyped to confirm monoclonal infections [54]. The IC50
values of individual parasite isolates are shown in Table S2.
Parasite isolates were generally sensitive to AS with a mean IC50 of
5.8 nM, but the range (1.4–16.5 nM) was relatively wide with an
almost 12-fold difference between the most and least susceptible
isolates (Table 1). The mean IC50s of the samples to DHA ranged
from 9.6 to 40.3 nM with a mean IC50 of 23.0 nM. The mean
IC50 for MQ was 50.5 nM, ranging from 16.2 to 96.2 nM, with
a six-fold difference in IC50 between the most and the least
susceptible isolates. The parasites had a mean IC50 of 5.9 nM for
LMF with a fairly narrow range of 3.0–11.5 nM. Compared with
the mean values of the control laboratory clone 3D7, only MQ
sensitivity showed a significant difference after Bonferroni
correction (P,0.05). When the IC50 data were stratified by years,
slight variations were observed between the years (Figure 1).
However, none of the comparisons were statistically significant
(P.0.05, t-test). Also noteworthy is the detection of several outlier
isolates (greater than 2 standard deviation), which showed much
higher IC50 values to all drugs.
Correlations between the IC50s of the four antimalarial drugs
were evaluated using the Spearman’s test (Table 2). There was
a highly significant correlation between responses to the two
artemisinin derivatives (P,0.0001). When all samples were
considered, we did not detect significant correlation between the
two aminoalcohol drugs MQ and LMF (P.0.05). However, when
only the samples collected in 2009 were compared, a modest
correlation was found between MQ and LMF (P,0.05) (data not
shown).
Polymorphisms in Candidate Target Genes
Pfmdr1. We genotyped pfmdr1SNPs by PCR and sequencing
in the 51 field isolates, focusing on the known amino acid
substitutions at codons 86 (N/Y), 184 (Y/F), 1034 (S/C), 1042 (N/
D), and 1246 (D/Y). Wild-type haplotype was prevalent and
accounted for ,65%. Except codon 184, mutations at other
codons were rare (Table 3). Specifically, mutations at codons 1034
and 1246 were not observed. The N86Y mutation, which is
associated with CQ resistance and increased sensitivity to MQ and
artemisinin [57], was detected only in one (2%) isolate of the
samples. The N1042D mutation associated with QN resistance
was also rare and found only in 4 (7.8%) isolates of the samples
[18]. The C-terminal mutation haplotype 1034C/1042D/1246Y,
which is prevalent in South America and enhances parasite
susceptibility to MQ and artemisinin, was absent in our samples
(Table 3). We did not detect pfmdr1 amplification in any samples;
the 51 isolates had a mean pfmdr1 copy number value of
1.0260.14 (Figure S1).
Pfcrt. The key determinant of CQ resistance K76T was
ubiquitously present in all samples. Further, the A220S mutation
almost reached fixation and was found in 50/51 parasite isolates
(data not shown).
PfATP6. We obtained complete sequences of the PfATP6
coding region in 51 samples and compared them with that from
3D7. Mutations were rare and sporadic with a total of five
identified (Table 3). Three mutations have been described
previously (I89T, A438D and N465S), and two were novel
mutations (I226V and E710K). Except for the I89T and A438D
Table 1. In vitro IC50s (nM) of 3D7 and 51 culture-adapted
clinical isolates to four antimalarial drugs.
Drug
3D7
(Mean 6 SD) Clinical isolates
Mean 6 SD Range
Artesunate 5.461.5 5.862.8 1.4–16.5
Dihydroartemisinin 22.162.0 23.067.4 9.6–40.4
Mefloquine 40.7611.7 50.4617.8* 16.2–96.2
Lumefantrine 7.1262.1 5.961.7 3.0–11.5
IC50 values are shown as mean 6 standard deviation (SD). The mean IC50 of
each clinical isolate was used to calculate the mean IC50 and SD for all isolates.
The range of IC50 values of all clinical isolates is also shown for each drug. t-tests
were used to compare the IC50 values between test samples and laboratory
clone 3D7. Asterisk (*) indicates statistically significant difference from 3D7 after
a Bonferroni correction (P,0.0009).
doi:10.1371/journal.pone.0030927.t001
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mutations, which occurred in 5 (9.8%) and 3 (5.9%) isolates of the
samples, respectively, the remaining mutations were only detected
once in the samples. The L263E and S769N mutations, which
have been proposed to confer artemisinin resistance [30,31], were
not detected in our samples. A total of seven haplotypes were
detected; 43 (84.3%) were wild-type, whereas six and two samples
contained single and two mutations, respectively.
Figure 1. In vitro drug responses. IC50s (nM) of P. falciparum isolates to artesunate (AS), dihydroartemisinin (DHA), mefloquine (MQ) and
lumefantrine (LMF) are stratified by year. Solid boxes (&) indicate the mean values; the error bars denote one standard deviation. For IC50 values of
each drug, there was no significant differences between the years (P.0.05, t-test).
doi:10.1371/journal.pone.0030927.g001
Table 2. Correlation matrix showing Spearman’s correlation coefficients between the four tested drugs.
Mefloquine Lumefantrine Dihydroartemisinin Artesunate
Mefloquine 2
Lumefantrine 0.2060 2
Dihydroartemisinin 20.0056 0.2316 2
Artesunate 0.2523 0.1991 0.5494* 2
*indicates P#0.0001.
doi:10.1371/journal.pone.0030927.t002
P. falciparum Drug Resistance and Candidate Genes
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Pfmdr6. Analysis of the coding region of the pfmdr6 gene
from 51 parasite samples revealed mutations at residues 175 and
353 (Table 3). The Y175S mutation was found in 9 (17.7%)
isolates, whereas L353W mutation was only found in one sample.
In addition, this gene harbored two deletions. The tri-peptide SIN
corresponding to positions 735–737 in 3D7 was deleted in four
isolates, while the N residue at residue 823 was deleted in 45
(88.2%) isolates. Other polymorphisms all occurred in repeat
sequences. For the microsatellite sequence corresponding to
positions 103–110 in 3D7 (referred to as repeat R1), the number
of the amino acid N ranged from 6 (in 3D7) to 12, with 8 as the
predominant one occurring in 39 (76.5%) isolates. 3D7 had two
NI repeats at positions 267–270 (referred to as repeat R2).
Whereas 50 (98.0%) isolates had two NI repeats, only one field
isolate had three NI repeats. The third repeat sequence, referred
to as repeat R3, contains NIN repeats at positions corresponding
to 717–734 in 3D7. Whereas 46 (90.2%) isolates had 6 NIN
repeats, 4 (7.8%) and 1 (2.0%) isolates had 5 and 4 NIN repeats,
respectively. These polymorphisms gave rise to a total of 13
haplotypes (Table 3), but none of the field isolates had the same
haplotype as 3D7. The most prevalent haplotype, which differs
from 3D7 by 8 N residues in microsatellite repeats R1 and a codon
819 deletion, occurred in 25 (49.0%) parasite isolates.
PfMT. Sequencing of the pfMT gene detected a total of two
amino acid substitutions at positions 30 and 286. The I30N
mutation was found in all but one parasite isolate, whereas the
S286C mutation was rare and found only in one isolate. In
addition, the codon for amino acid N496 was deleted in the
majority (94.1%) of the isolates. A total of four amino acid
haplotypes were recognized with one (N30/286S/496–) account-
ing for 94.1% parasite isolates (Table 3). In comparison, all other
haplotypes only occurred once in the samples.
Correlation between Polymorphisms and in vitro Drug
Sensitivities
Since the pfcrt K76T mutation was fixed and the A220S
mutation almost reached fixation (50/51), and no pfmdr1amplifica-
tion was detected in the studied parasite populations, associations
could not be evaluated between these markers and drug responses.
Thus, we analyzed the potential associations between point
mutations in pfmdr1, pfATP6, pfmdr6, and pfMT genes and
drug responses. None of the mutations in the pfmdr1 and pfATP6
genes had a significant association with altered responses to AS
and DHA. Yet, the N1042D mutation in pfmdr1was found to be
associated with increased susceptibility to MQ (Figure 2, Table
S3). SNPs in pfmdr6 and pfMT genes that caused amino acid
substitutions were rare. None of them was associated with
significantly altered sensitivity to the four drugs tested (P.0.05).
Neither did the deletion mutations (S7352/I7362/N737– and
N823– in pfmdr6, as well as N496– in pfMT) affect the sensitivity
to the four drugs. There are three simple amino acid repeats in
pfmdr6. Whereas no significant differences in drug sensitivity were
detected between the parasites carrying different numbers of
repeats in repeats R2 and R3, parasites carrying 9 repeats in
repeat R1 were associated with significantly increased resistance to
DHA (P,0.05) (Figure 2, Table S3). The difference between
parasites carrying 8 and 9 R1 repeats remained significant after
Bonferroni correction (Figure 2). In addition, 7 repeats in R1 were
also significantly correlated with reduced sensitivity to LMF
(P,0.05) (Table S3).
To determine whether certain haplotypes of pfmdr1, pfATP6,
pfmdr6, and pfMT genes are associated with altered drug responses,
we compared the drug responses of the mutant haplotypes with
those of the wild-type isolates. Comparison of pfmdr1 haplotypes
with $3 (5.9%) prevalence showed that parasites carrying the
pfmdr1 1042D mutation showed increased sensitivity to MQ,
whereas responses to other three drugs were not significantly
different between the pfmdr1 haplotypes (Figure 3). All mutant
haplotypes of pfATP6 were below 4% in prevalence, and only 2
(3.9%) parasite isolates with the 89T/438D double mutations had
significantly higher IC50 values to AS (data not shown). For the
pfmdr6 gene, we found a significant association for the haplotype
carrying 9 N residues in microsatellite repeat R1 (9Y2L6+–) with
significantly higher DHA IC50 values when compared to both 3D7
and the haplotype 8Y2L6+–. These findings remained significant
Table 3. Amino acid substitutions and resulting haplotypes
in four studied genes from 51 parasite isolates.
Gene Mutation No. (%) Haplotypes No. (%)
Pfmdr1
(86/184/1042)
N86Y 1 (2.0) NYN{ 33 (64.7)
Y184F 14 (27.5) NFN 13 (25.5)
N1042D 4 (7.8) NYD 3 (5.9)
YYN 1 (2.0)
NFD 1 (2.0)
PfATP6
(89/226/438/465/710)
I89T 5 (9.8) IIAEG{ 43 (84.3)
I226V 1 (2.0) TIAEG 2 (3.9)
A438D 3 (5.9) TIDEG 2 (3.9)
N465S 1 (2.0) TIAKG 1 (2.0)
E710K 1 (2.0) IIDEG 1 (2.0)
IVAEG 1 (2.0)
IIAKG 1 (2.0)
Pfmdr6*
(R1/175/R2/353/R3/
SIN/823)
Y175S 9 (17.7) 6 Y2L6+N{ 0
L353W 1 (2.0) 8 Y2L6+– 25 (49.0)
N823– 45 (88.2) 8 S2L6+– 5 (9.8)
8 S2L6+N 4 (7.8)
9 Y2L6+– 4 (7.8)
8 Y2L5–– 3 (5.9)
6 Y2L6+– 2 (3.9)
10Y2L6+– 2 (3.9)
6 Y2W6+– 1 (2.0)
7 Y2L6+– 1 (2.0)
8 Y2L6+N 1 (2.0)
8 Y3L6+– 1 (2.0)
11Y2L52N 1 (2.0)
12Y2L4+– 1 (2.0)
PfMT
(30/286/496)
I30N 50 (98.0) ISN{ 1 (2.0)
S286C 1 (2.0) NS– 48 (94.1)
N496– 48 (94.1) NSN 1 (2.0)
NCN 1 (2.0)
{denotes the reference haplotype in 3D7; Letters in bold indicate mutated
amino acids; - indicates deletion of the residue. No. (%) indicates the number
and percentage of isolates harboring these mutations or haplotypes.
*The mdr6 haplotypes: R1 repeats, number of N at positions 103–110; R2,
number of NI at positions 267–270, R3, number of NIN at positions 717–734; the
tri-peptide SIN at position 735–737 are shown as + (present) or – (deleted).
doi:10.1371/journal.pone.0030927.t003
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after Bonferroni correction (Figure 3). Furthermore, haplotype
8Y2L6+– showed significantly lower IC50s to LMF when
compared to the wild-type 3D7. Interestingly, all of the haplotypes
showed increased sensitivity to LMF when compared to 3D7. In
comparison, none of the haplotypes in pfMT were associated with
altered drug sensitivity (data not shown).
Discussion
The GMS in Southeast Asia has been a breeding ground of
antimalarial drug resistance, where MDR parasites have emerged.
Parasites in this region appear to have the ARMD (accelerated
resistance to multiple drugs) genetic background, favoring de-
velopment of resistance to new antimalarial drugs [58,59]. Further
reflecting such a tendency, malaria parasites from this region have
recently been found to exhibit reduced susceptibility or low-grade
resistance to artemisinin derivatives [3,4]. This urgent situation
calls for closer surveillance, containment and heightened research
on resistance mechanisms. In some areas of the GMS such as the
China-Myanmar border area, artemisinins have been used for
over three decades, mostly as monotherapies prior to 2005. Earlier
in vitro assays have already detected a trend of declining sensitivity
to AS [46]. Surveillance at the Thai-Myanmar border also
detected reduced sensitivity to artemisinins, MQ, and QN [60–
62]. Therefore, understanding whether artemisinin-resistant para-
sites have spread to neighboring regions or emerged elsewhere in
the GMS is essential for coordinating containment efforts. Here,
we evaluated this situation at the China-Myanmar border area
and assessed the in vitro sensitivity of recently collected parasite
isolates to artemisinins and two amino alcoholic drugs. Our data
showed that although these parasites were generally sensitive to
AS, there were eight parasite isolates showing mean IC50 values
above 8 nM. In addition, in vitro sensitivity to DHA also had a more
than 4-fold variation. Spearman’s correlation test detected
significant correlations in sensitivity between the two artemisinin
derivatives, suggesting that these drugs have shared cellular
targets. Despite the fact that no careful clinical studies have been
conducted in this region to rule out the lack of clinical resistance to
artemisinins, our data suggest that reduced susceptibility to the
artemisinins might have already emerged in some isolates (outliers)
in the study parasite population. Therefore, close monitoring of
resistance development at such sentinel sites is necessary. We have
also included two aminoalcoholic drugs in the in vitro assays, since
responses to MQ and LMF are often correlated with those to
artemisinins [18,61]. At the China-Myanmar border area, MQ
has never been deployed, but in vitro assays suggested the existence
of reduced sensitivity to MQ with 37 parasite isolates showing
higher mean IC50 values than 3D7. Another perplexing finding is
that the parasite isolates tested were highly sensitive to LMF,
which is in sharp contrast to the parasites from Thailand that
displayed more than 20-fold higher IC50s [63], although LMF has
not been used in Thailand. The decreased sensitivity to LMF in
Thailand could be related to the mass deployment of MQ in
treating falciparum malaria, since sensitivities to MQ and LMF
are correlated. Similarly, our samples collected in 2009 also
showed significant correlation in IC50 values between these two
drugs. However, none of these two aminoalcoholic drugs showed
positive correlation in IC50 with the two artemisinin drugs. These
are different from the in vitro drug studies carried out in other areas
of the GMS [61,64–66]. The reason for such discrepancies was not
clear, but may be related to the divergent antimalarial drug
policies in these areas.
While the mode of action of artemisinins is not completely
understood, several cellular targets have been proposed. Among
them, PfATP6 has been suggested as a prime candidate target of
artemisinins [29,30], and studies with field parasite isolates from
French Guiana seemed to support this suggestion [31]. However,
since these reports, results from subsequent studies appear to
contradict the hypothesis of PfATP6 as a specific target of
artemisinins. First, artemisinin treatment of P. falciparum did not
alter the morphology of endoplasmic reticulum, where PfATP6 is
supposed to be localized [67]. Second, purified recombinant
Figure 2. Association of SNPs and other polymorphisms in candidate genes with drug responses. Only significant association of a SNP in
pfmdr1 and number variation of repeat R1 in pfmdr6 with in vitro responses to artesunate (AS), dihydroartemisinin (DHA), mefloquine (MQ) and
lumefantrine (LMF) are plotted here. IC50 values are shown as mean + standard deviation. *indicates significant difference (P,0.05) in sensitivity
between the two alleles.
doi:10.1371/journal.pone.0030927.g002
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PfATP6 did not seem to bind artemisinins, nor was it inhibited by
artemisinins [68,69]. Third, allelic exchange experiments aiming
to determine whether the PfATP6 L283E mutation is linked to
a drastic reduction of artemisinin sensitivity only provided
tangential evidence supporting this suggestion [70]. In addition,
our recent allelic exchange experiment did not detect differences
in sensitivity to artemisinin derivatives between parasites carrying
either S769 or 769N [71]. Further, an African parasite isolate
carrying the S769N mutation did not show increased resistance to
artemisinins [34]. In the Thai-Cambodian border region, where
resistance to artemisinins has recently emerged, these two
mutations have not been detected either [42]. We and others
further confirmed the lack of these mutations in parasites from the
China-Myanmar border area, where artemisinins have been
deployed extensively for over 30 years [38]. In fact, most parasites
from our study carried the wild-type PfATP6 gene, and no
significant association could be established between the rare
mutations in pfATP6 and artemisinin resistance. Collectively, these
data potentially suggest that PfATP6 might not play a major and
direct role in artemisinin resistance.
The malaria parasite encodes many transporters and some of
them such as pfcrt, pfmdr1 and pfmrp have been strongly connected
with antimalarial drug resistance [72–74]. Parasite resistance to
multiple drugs has been associated with SNPs and increased copy
number of the ABC transporter family member pfmdr1. Pfmdr1
amplification is correlated with resistance to MQ, QN, HF, and
artemisinins [20,75]. Laboratory experiments confirmed that an
increase of pfmdr1 copy number can be induced by stepwise MQ
selection [76], whereas knockdown of pfmdr1 expression results in
increased susceptibility to MQ, QN, and artemisinin [77].
Moreover, recent laboratory selection studies strongly implicated
pfmdr1 gene amplification as a major determinant of induced
artemisinin resistance [78,79]. Pfmdr1 also harbors many point
mutations: the 86Y mutation which modifies resistance to CQ is
associated with increased sensitivity to MQ and artemisinin [16],
whereas mutations at the C-terminal end, which are prevalent in
South America, contribute to QN resistance but enhance MQ and
artemisinin sensitivity [18]. Consistently, administration of arte-
mether-LMF has selected for increased frequency of the N86 allele
[32,80]. In Thailand and Cambodia, pfmdr1 gene amplification has
become increasingly prevalent in field parasite populations and
was responsible for resistance to MQ and declining efficacy of
ACTs [19,22,23,26,28]. In this case, pfmdr1 amplification has been
strongly tied to the extensive deployment of MQ in this region. At
the China-Myanmar border, however, pfmdr1 gene amplification
has not been observed, consistent with the fact that MQ has never
been used in this region. Overall, the frequencies of pfmdr1 N86Y
and C-terminal mutations which confer increased sensitivity to
Figure 3. Association of haplotypes in candidate genes with drug responses. Only association of major haplotypes in pfmdr1 and pfmdr6
with in vitro responses to artesunate (AS), dihydroartemisinin (DHA), mefloquine (MQ) and lumefantrine (LMF) are plotted. IC50 values are shown as
mean + standard deviation. * indicates significant difference (P,0.05) in sensitivity between the haplotypes after Bonferroni correction. # indicates
that this pfmdr6 haplotype was significantly more sensitive to LMF than 3D7.
doi:10.1371/journal.pone.0030927.g003
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artemisinins were very low in the GMS [61,64]. Our results from
the China-Myanmar border further verified these findings [81].
Yet, despite the implied significance of pfmdr1 in artemisinin
resistance, in our study, pfmdr1 was not associated with the reduced
artemisinin susceptibility recently unveiled in western Cambodia
[42]. The uncommon pfmdr1 polymorphisms from these parasites
offer opportunities for investigations of mechanisms other than
pfmdr1.
The clear link between polymorphisms of transporter genes and
antimalarial drug resistance has prompted us to evaluate other
genes encoding putative transporters. We have chosen pfmdr6,
another ABC transporter family member, and pfMT, a putative
metabolite/drug transporter, since these two genes have been
shown to be under recent positive selection from a genome-wide
association study [43]. Both genes were found to harbor small
numbers of nonsynonymous SNPs, whereas pfmdr6 also have
polymorphisms in three simple repeats. Compared with 3D7, the
Y175S mutation and the 823 codon deletion had reached 17.7 and
88.2% of prevalence, respectively. However, none of the point
mutations were associated with altered drug sensitivity. Yet, the
microsatellite repeat R1, which has seven different alleles (ranging
from 6 to 12 repeats), appeared to affect the in vitro sensitivity to
DHA. Specifically, 9 Ns in R1 was associated with reduced
sensitivity to DHA. This is reminiscent of the effect of the
microsatellite repeats in the pfNHE1 gene on in vitro sensitivity to
QN [50,82]. Of the 13 haplotypes detected within this gene, 8
were rare haplotypes, each being represented by one or two
isolates. Again, the haplotype with 9 Ns in R1 was associated with
significantly higher IC50 value to DHA than others. Compared to
3D7, two mutations in pfMT (I30N and N496–) were pre-
dominant in the samples analyzed, which together gave rise to
a predominant haplotype. Correlation studies did not detect any
association of the mutations or haplotypes with significant altered
drug sensitivity. However, we would like to exercise caution in this
finding since previous in vitro studies of parasite resistance to AS
have shown poor correlations with clinical in vivo studies.
Furthermore, significant associations between these rare haplo-
types and drug responses were at most based on a small number of
parasite isolates carrying such mutations. Therefore, such an
association may not hold if more samples carrying these mutations
were analyzed.
Despite extensive efforts aimed at elucidating the mechanism of
artemisinin resistance in P. falciparum using the candidate gene
approach, most of the mutations encountered in candidate genes
did not account for reduced sensitivity to artemisinins in parasites
from clinical studies in western Cambodia [42]. Our in vitro studies
using parasites from the China-Myanmar border area seem to
convey a similar conclusion. However, analysis of parasites
originating from the Thai-Myanmar border region implied that
pfmdr1 copy number and a new point mutation (F1226Y) are
significantly associated with in vitro response to artemisinins [65].
This discrepancy may reflect the intrinsic difference between in
vitro assay and in vivo clinical studies. In addition, it may also be due
to divergent genetic backgrounds of the parasite populations, since
the significance of pfmdr1 point mutations for CQ and QN
resistance appears to depend on the genetic background of the
parasites [17,18]. Meanwhile, another very relevant finding of this
study is the existence of dramatic differences in drug responses and
genotypes between our studied parasite population and other
populations in the GMS. As malaria control is being intensified,
geographical separation of parasite populations will occur.
Differences in regional drug policy will inevitably exert distinctive
selection pressures on parasites. Therefore, investigations into drug
resistance mechanisms using different populations may help define
the bona fide genetic determinants of artemisinin resistance.
Furthermore, since artemisinin resistance appears to be a multi-
genic trait, mutations in multiple genes may have cumulative
effects on parasite’s response to artemisinins. Consequently,
genetic analysis at multiple loci and association studies with
combined haplotypes may generate meaningful insights into the
mechanisms of artemisinin resistance [65]. Genome-wide ap-
proaches such as SNP array and deep sequencing technologies
may be crucial in identifying the molecular basis of the artemisinin
resistance. It is also imperative that close resistance surveillance be
continued at sentinel sites where artemisinins have been deployed
extensively in the past so that the emergence and spread of
artemisinin resistance is carefully monitored.
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